After confirming the downregulation of SAMD5 in breast cancer, SAMD5 overexpression was achieved in two TNBC cell lines (MDA-MB-231 and HCC1937) by introducing SAMD5 overexpression and validated using RT-qPCR and immunoblotting for further functional investigations (Figure 6A and Figure 6C). This evidence concerns the gene SAMD5 and breast carcinoma.